CSRxP Applauds FDA’s Biosimilars Action Plan
Jul 18, 2018
“We applaud Commissioner Gottlieb and the FDA for their leadership on… Read More
© 2024 CSRXP- All Rights Reserved
Statements
CSRxP Releases Comments on Drug Price Blueprint
Jul 13, 2018
The Department of Health and Human Services is taking a good first step in the… Read More
CSRxP Statement on Novartis’ $475,000 Price Tag for Kymriah
Aug 30, 2017
"While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point." Read More
CSRxP Calls for Action on CREATES Act
Jul 27, 2017
CSRxP Calls for Action on CREATES Act The Campaign for Sustainable Rx Pricing… Read More
CSRxP Releases Powerful Testimonial: “Debbie’s Story”
Jul 10, 2017
CSRxP Releases Powerful Testimonial: “Debbie’s Story” The… Read More
CSRxP Applauds Introduction of the CREATES Act
Apr 27, 2017
“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety." Read More
Analysis Shows New Cholesterol Medications Are Not Cost Effective
Aug 16, 2016
"The dangerous trend of high-priced drugs has to be reversed and a common-sense solution like measuring the value and cost-effectiveness of medications is one necessary step to fix the broken prescription drug market, but it must also be combined with increased transparency and competition.” Read More
CSRxP Statement on Launch of AstraZeneca’s Crestor
Jul 21, 2016
“We are glad to see that the court rejected AstraZeneca’s effort to abuse the Orphan Drug Act and restrict generic competitors to Crestor,” said John Rother. “Additional competition in the prescription drug market—including generic options—is crucial to lowering prescription drug prices and providing patients with more affordable choices.” Read More
CSRxP Statement on the Costly New Abuse-Deterrent Drug Provision
Jul 8, 2016
"With this provision, policymakers are rewriting the rules to benefit pharmaceutical manufacturers for slightly tweaking their product and reintroducing it as a new 'innovation,’” CSRxP Executive Director John Rother said. Read More
CSRxP Statement on AstraZeneca seeking “Orphan Drug” designation for widely-used cholesterol drug Crestor
Jun 30, 2016
“Abusing rules and regulations to keep competitors out of the market is common in the prescription drug industry, but AstraZeneca’s latest undertaking is especially egregious." Read More
CSRxP Statement on New Data Showing Best-Selling Drug Prices Rising at Twice the Rate of Inflation
Jun 30, 2016
"When the sticker price for 30 out of 39 of the most sold drugs goes up by more than double the rate of inflation, consumers are left holding the bag. These price increases year after year compound the problem and the whole scheme is unsustainable.” Read More
CSRxP Statement on Medicare Trustees Report
Jun 22, 2016
"Prescription drug costs are rising much faster than other parts of Medicare and putting ever greater financial pressure on the program and on its beneficiaries. It’s no wonder that voters are making prescription drug prices a top issue in this election." Read More